Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis

Detalles Bibliográficos
Autores principales: Goel, Ruchika, Morgan, Matthew, Chanouzas, Dimitrios, Caplan, Joshua, Logan, Sarah, Harper, Lorraine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Letter to the Editor (Other)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496757/
https://www.ncbi.nlm.nih.gov/pubmed/34632259
http://dx.doi.org/10.1093/rap/rkab039
_version_ 1784579816275574784
author Goel, Ruchika
Morgan, Matthew
Chanouzas, Dimitrios
Caplan, Joshua
Logan, Sarah
Harper, Lorraine
author_facet Goel, Ruchika
Morgan, Matthew
Chanouzas, Dimitrios
Caplan, Joshua
Logan, Sarah
Harper, Lorraine
author_sort Goel, Ruchika
collection PubMed
description
format Online
Article
Text
id pubmed-8496757
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-84967572021-10-08 Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis Goel, Ruchika Morgan, Matthew Chanouzas, Dimitrios Caplan, Joshua Logan, Sarah Harper, Lorraine Rheumatol Adv Pract Letter to the Editor (Other) Oxford University Press 2021-07-16 /pmc/articles/PMC8496757/ /pubmed/34632259 http://dx.doi.org/10.1093/rap/rkab039 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor (Other)
Goel, Ruchika
Morgan, Matthew
Chanouzas, Dimitrios
Caplan, Joshua
Logan, Sarah
Harper, Lorraine
Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
title Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
title_full Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
title_fullStr Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
title_full_unstemmed Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
title_short Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
title_sort rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of anca-associated vasculitis
topic Letter to the Editor (Other)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496757/
https://www.ncbi.nlm.nih.gov/pubmed/34632259
http://dx.doi.org/10.1093/rap/rkab039
work_keys_str_mv AT goelruchika rituximab500mg6monthlyinfusionsisanoptioninmaintenancetherapyofancaassociatedvasculitis
AT morganmatthew rituximab500mg6monthlyinfusionsisanoptioninmaintenancetherapyofancaassociatedvasculitis
AT chanouzasdimitrios rituximab500mg6monthlyinfusionsisanoptioninmaintenancetherapyofancaassociatedvasculitis
AT caplanjoshua rituximab500mg6monthlyinfusionsisanoptioninmaintenancetherapyofancaassociatedvasculitis
AT logansarah rituximab500mg6monthlyinfusionsisanoptioninmaintenancetherapyofancaassociatedvasculitis
AT harperlorraine rituximab500mg6monthlyinfusionsisanoptioninmaintenancetherapyofancaassociatedvasculitis

Ejemplares similares